Sinclair licenses rights to Dr. Reddy

LONDON Sinclair Pharma has licensed the exclusive rights of its seborrheic dermatitis product, Sebclair, to the U.S. subsidiary of Dr. Reddy’s Laboratories’.

Dr. Reddy’s will market the product in the U.S. under a new brand name through its dermatology division. Upon commercialization of the product, Sinclair said it would receive royalty payments based on net sales.

Dr. Reddy’s expects to launch the product within a year.